{"id":2589,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2010-11-13","marketCap":419.2381286621094,"name":"Arbutus Biopharma Corp","phone":"16044193200","outstanding":167.6999969482422,"symbol":"ABUS","website":"https://www.arbutusbio.com/","industry":"Biotechnology"},"price":2.50125,"year":2024,"month":1,"day":5,"weekday":"Friday","title":"Impact of currency fluctuations on Arbutus Biopharma Corp multinational stock","date":"2024-01-05","url":"/posts/2024/01/05/ABUS","content":[{"section":"Introduction","text":"Arbutus Biopharma Corp is a multinational company that operates in various countries and deals with different currencies. Changes in currency exchange rates can impact the company's financial performance."},{"section":"Revenue Impact","text":"Currency fluctuations can directly impact Arbutus Biopharma Corp's revenues. For example, if the foreign currency in which the company generates sales depreciates against the company's reporting currency (e.g., USD), the reported revenue figures in USD will be lower. This can result in a decrease in stock value as investors may perceive lower revenue growth."},{"section":"Cost Impact","text":"Currency fluctuations can also affect Arbutus Biopharma Corp's costs. If the company's costs, such as research and development expenses or raw material purchases, are denominated in a foreign currency that appreciates against the reporting currency, it can lead to higher costs and reduced profitability."},{"section":"Competitiveness and Market Share","text":"Currency fluctuations can impact Arbutus Biopharma Corp's competitiveness in international markets. A strong local currency can increase the company's prices in foreign markets, making its products less competitive compared to local manufacturers. Conversely, a weak local currency can make the company's products more affordable and boost market share."},{"section":"Hedging Strategies","text":"To mitigate currency risk, companies like Arbutus Biopharma Corp often employ hedging strategies. These strategies involve using financial instruments like futures contracts or options to reduce exposure to currency fluctuation. By hedging, the company can lock in exchange rates and protect against potential losses caused by adverse currency movements."},{"section":"Real-World Case Study 1: Brexit and Pound Sterling","text":"When the United Kingdom voted to leave the European Union (Brexit) in 2016, it caused significant fluctuations in the value of the British Pound. Arbutus Biopharma Corp, which has operations in the UK, experienced currency-related challenges. The depreciation of the Pound led to lower reported revenues in USD, impacting investor sentiment and stock performance."},{"section":"Real-World Case Study 2: Emerging Market Currency Crisis","text":"In 2018, several emerging market currencies, such as the Turkish Lira and Argentine Peso, experienced sharp depreciations due to economic and political factors. Arbutus Biopharma Corp, operating in these countries, faced increased costs as raw material prices surged. This negatively affected profitability and investor confidence in the company's stock."},{"section":"Conclusion","text":"Currency fluctuations pose both risks and opportunities for Arbutus Biopharma Corp. While they can impact revenues, costs, and market competitiveness, effective hedging strategies can help mitigate these risks. A balanced approach to currency risk management is crucial for multinational companies to navigate the volatile global economy."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1704108099,"headline":"Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company","id":124793854,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ABUS","publisher":"Yahoo","summary":"Key Insights Significant control over Arbutus Biopharma by individual investors implies that the general public has...","url":"https://finance.yahoo.com/news/institutions-own-30-arbutus-biopharma-112139275.html"}]}